Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Research Report 2023

Publication ID:

PB502234249

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Graft versus Host disease occurs after a stem cell or bone marrow transplant. High dose treatment destroy cancer cells along with that it simultaneously destroys healthy cells. Stem cell and bone marrow transplant treatments are used in reconstructing damaged cells, surrounding cancer tumors. Normally after high dose treatment, patient receives bone marrow from a donor through drip which resumes production of blood cells. Graft versus Host Disease occurs when certain types of white blood cells. This is caused due to the transplanted cells (graft) see recipient鈥檚 body (host) as exotic, thus transplanted cells attack the host body.
Highlights
The global Graft Versus Host Disease (GVHD) Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The growing number of organ transplantation cases as one of the major factors that will have a positive impact on the growth of the market. The rise in chronic diseases across the globe has led to the growth in the need for organ transplantation. It has been observed that in 2015, the US witnessed more than 30,000 organ transplants cases, which has increased about 5% when compared to the previous year. Similarly, countries such as Australia also witnesses increasing cases of organ transplantation. This rising number of organ transplants will subsequently augment the growth prospects of the GVHD treatment market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Graft Versus Host Disease (GVHD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Graft Versus Host Disease (GVHD) Treatment.
The Graft Versus Host Disease (GVHD) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Graft Versus Host Disease (GVHD) Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Graft Versus Host Disease (GVHD) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
GlaxoSmithKline
Glenmark
Kadmon Holdings
Osiris Therapeutics
Sanofi
Takeda
Segment by Type
Monoclonal Antibodies
MTOR Inhibitors
Tyrosine Kinase Inhibitors
Thalidomide
Etanercept
Segment by Application
Acute Graft Versus Host Disease (aGvHD)
Chronic Graft Versus Host Disease (cGvHD)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Graft Versus Host Disease (GVHD) Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 MTOR Inhibitors
1.2.4 Tyrosine Kinase Inhibitors
1.2.5 Thalidomide
1.2.6 Etanercept
1.3 麻豆原创 by Application
1.3.1 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Acute Graft Versus Host Disease (aGvHD)
1.3.3 Chronic Graft Versus Host Disease (cGvHD)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Perspective (2018-2029)
2.2 Graft Versus Host Disease (GVHD) Treatment Growth Trends by Region
2.2.1 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Graft Versus Host Disease (GVHD) Treatment Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Graft Versus Host Disease (GVHD) Treatment Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Dynamics
2.3.1 Graft Versus Host Disease (GVHD) Treatment Industry Trends
2.3.2 Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Drivers
2.3.3 Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Challenges
2.3.4 Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease (GVHD) Treatment Players by Revenue (2018-2023)
3.1.2 Global Graft Versus Host Disease (GVHD) Treatment Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Graft Versus Host Disease (GVHD) Treatment Revenue
3.4 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease (GVHD) Treatment Revenue in 2022
3.5 Graft Versus Host Disease (GVHD) Treatment Key Players Head office and Area Served
3.6 Key Players Graft Versus Host Disease (GVHD) Treatment Product Solution and Service
3.7 Date of Enter into Graft Versus Host Disease (GVHD) Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease (GVHD) Treatment Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted 麻豆原创 Size by Type (2024-2029)
5 Graft Versus Host Disease (GVHD) Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease (GVHD) Treatment Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Graft Versus Host Disease (GVHD) Treatment Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size (2018-2029)
6.2 North America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2018-2023)
6.4 North America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size (2018-2029)
7.2 Europe Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2018-2023)
7.4 Europe Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size (2018-2029)
9.2 Latin America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Graft Versus Host Disease (GVHD) Treatment 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Introduction
11.1.4 Bristol-Myers Squibb Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Abbott
11.2.1 Abbott Company Detail
11.2.2 Abbott Business Overview
11.2.3 Abbott Graft Versus Host Disease (GVHD) Treatment Introduction
11.2.4 Abbott Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.2.5 Abbott Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Introduction
11.3.4 AbbVie Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.3.5 AbbVie Recent Development
11.4 Allergan
11.4.1 Allergan Company Detail
11.4.2 Allergan Business Overview
11.4.3 Allergan Graft Versus Host Disease (GVHD) Treatment Introduction
11.4.4 Allergan Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.4.5 Allergan Recent Development
11.5 Anterogen
11.5.1 Anterogen Company Detail
11.5.2 Anterogen Business Overview
11.5.3 Anterogen Graft Versus Host Disease (GVHD) Treatment Introduction
11.5.4 Anterogen Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.5.5 Anterogen Recent Development
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Detail
11.6.2 Astellas Pharma Business Overview
11.6.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Introduction
11.6.4 Astellas Pharma Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.6.5 Astellas Pharma Recent Development
11.7 Athersys
11.7.1 Athersys Company Detail
11.7.2 Athersys Business Overview
11.7.3 Athersys Graft Versus Host Disease (GVHD) Treatment Introduction
11.7.4 Athersys Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.7.5 Athersys Recent Development
11.8 Caladrius
11.8.1 Caladrius Company Detail
11.8.2 Caladrius Business Overview
11.8.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Introduction
11.8.4 Caladrius Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.8.5 Caladrius Recent Development
11.9 Eli Lilly
11.9.1 Eli Lilly Company Detail
11.9.2 Eli Lilly Business Overview
11.9.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Introduction
11.9.4 Eli Lilly Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.9.5 Eli Lilly Recent Development
11.10 GlaxoSmithKline
11.10.1 GlaxoSmithKline Company Detail
11.10.2 GlaxoSmithKline Business Overview
11.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Introduction
11.10.4 GlaxoSmithKline Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.10.5 GlaxoSmithKline Recent Development
11.11 Glenmark
11.11.1 Glenmark Company Detail
11.11.2 Glenmark Business Overview
11.11.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Introduction
11.11.4 Glenmark Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.11.5 Glenmark Recent Development
11.12 Kadmon Holdings
11.12.1 Kadmon Holdings Company Detail
11.12.2 Kadmon Holdings Business Overview
11.12.3 Kadmon Holdings Graft Versus Host Disease (GVHD) Treatment Introduction
11.12.4 Kadmon Holdings Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.12.5 Kadmon Holdings Recent Development
11.13 Osiris Therapeutics
11.13.1 Osiris Therapeutics Company Detail
11.13.2 Osiris Therapeutics Business Overview
11.13.3 Osiris Therapeutics Graft Versus Host Disease (GVHD) Treatment Introduction
11.13.4 Osiris Therapeutics Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.13.5 Osiris Therapeutics Recent Development
11.14 Sanofi
11.14.1 Sanofi Company Detail
11.14.2 Sanofi Business Overview
11.14.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Introduction
11.14.4 Sanofi Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.14.5 Sanofi Recent Development
11.15 Takeda
11.15.1 Takeda Company Detail
11.15.2 Takeda Business Overview
11.15.3 Takeda Graft Versus Host Disease (GVHD) Treatment Introduction
11.15.4 Takeda Revenue in Graft Versus Host Disease (GVHD) Treatment Business (2018-2023)
11.15.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Bristol-Myers Squibb
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Caladrius
Eli Lilly
GlaxoSmithKline
Glenmark
Kadmon Holdings
Osiris Therapeutics
Sanofi
Takeda

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.